Sign inJoin waitlistJoin the waitlist

Richard Francis Riedel

Professor of Medicine · Duke Department of Medicine

Credentials: ·

History

Duke Department of Medicine
Present
Duke Cancer Institute
Present

Jefferson Medical College of Thomas Jefferson University
2000

Research

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
The Lancet Oncology · 2017 · 1,203 citations
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors
Journal of the National Comprehensive Cancer Network · 2010 · 908 citations
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2018 · 495 citations

Kristen Ganjoo
21 papers
Margaret von Mehren
17 papers
SS
Scott Schuetze
17 papers
BT
Brian Van Tine
16 papers · 1 as a fellow
Steven Attia
15 papers
SC
Sant Chawla
12 papers
Brian Brigman
11 papers
Christian Meyer
11 papers
David Kirsch
10 papers
Lara Davis
10 papers
RM
Robert Maki
10 papers
Scott Okuno
10 papers

Clinical trials

Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia
Principal investigator · Terminated · Phase 1
Duke University
2012–2013
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
Site PI · Recruiting · Phase 3
Intensity Therapeutics, Inc.
2024–2028